RenovoRx (RNXT)

RenovoRx’s core technology is its Trans-Arterial Micro-Perfusion, or TAMP, platform. The system is designed to deliver an anti-cancer therapy through the arteries near a tumour, allowing the drug to penetrate the vessel wall and concentrate around the disease site. This localised intra-arterial delivery is intended to expose the tumour to therapeutic levels of medication while potentially reducing the broader toxicities associated with intravenous administration.

The company applies this platform to oncology indications with high unmet medical need, including pancreatic cancer. Its lead approach has involved pairing gemcitabine, a widely used chemotherapy, with targeted regional delivery. By focusing on the route and precision of delivery rather than relying solely on a novel active ingredient, RenovoRx seeks to enhance the usefulness of established cancer medicines in settings where treatment options remain limited.

As a clinical-stage business, RenovoRx does not resemble a mature pharmaceutical company with diversified commercial sales. Its value is closely linked to clinical trial results, regulatory progress, intellectual property protection, manufacturing and device logistics, and its ability to fund development. RNXT therefore offers exposure to a specialised oncology platform with potentially meaningful upside if targeted delivery proves clinically and commercially useful, but it also carries the significant development and approval risks typical of early biopharmaceutical companies.